Champions Oncology Inc. (CSBR) Sinks 7.05% After Earnings, Misses EPS, Misses Revenue
· Stocks · QuoteReporter
Post Earning Analysis
Champions Oncology Inc. (CSBR) Sinks 7.05% After Earnings, Misses EPS, Misses Revenue
Champions Oncology, Inc., founded in 1985 and headquartered in Hackensack, NJ, specializes in developing and selling innovative technology solutions for personalizing oncology drug development. Its flagship technology, TumorGraft, involves implanting human tumors into immune-deficient mice, offering a unique approach to tailoring cancer treatments. The company was established by James M. Martell and David Sidransky.
The current price of $7.25, reflecting today’s significant decline of -7.05%, suggests a recent bearish trend or negative market reaction. Despite this, the stock has recovered from its 52-week low of $4.61 by 57.27% and from the year-to-date low of $5.59 by 29.7%, indicating some resilience or positive shifts during the year.
The stock is currently trading below its 20-day and 50-day moving averages by 11.38% and 9.4% respectively, which signals a short-term bearish trend. However, it is slightly above the 200-day moving average by 0.57%, suggesting some long-term support or stabilization.
The week’s trading range between $6.74 and $8.31 shows volatility, with the price now closer to the lower end. The Relative Strength Index (RSI) at 60.94 leans towards overbought conditions, potentially indicating a pullback or consolidation phase soon. The Moving Average Convergence Divergence (MACD) of 0.05 is minimal, suggesting a lack of strong momentum in either direction.
Overall, the stock shows mixed signals with short-term pressures but potential long-term stability, warranting cautious optimism or a wait-and-see approach for investors.
Champions Oncology, Inc. (NASDAQ: CSBR) reported its financial results for the second quarter of fiscal 2026, revealing a revenue increase of 11% to $15.0 million from $13.5 million in the same quarter the previous year. Despite the rise in revenue, the company experienced a decline in net income, which decreased to $237,000 from $728,000 in Q2 2025. Adjusted EBITDA also fell to $843,000 from $1.1 million year-over-year.
The company’s cost of oncology revenue saw a slight reduction of 2.2% to $7.3 million. However, operating expenses surged by 16.4% to $14.9 million, primarily driven by significant increases in research and development, sales and marketing, and general and administrative expenses.
For the half-year, total revenue grew by 5.4% to $29.0 million, while net loss was reported at $230,000, contrasting with a net income of $2.1 million in the first half of 2025. Adjusted EBITDA for the half-year period decreased significantly to $962,000 from $3.2 million.
Despite these challenges, the company ended the quarter with strong cash reserves of approximately $8.5 million and no debt. Management remains optimistic about future growth, supported by ongoing investments in data platforms and business development. No dividends were declared, and no share repurchase was announced during the quarter.
Earnings Trend Table
| Date | Estimate EPS | Reported EPS | Surprise % | |
|---|---|---|---|---|
| 0 | 2025-12-15 | 0.08 | 0.02 | -75.00 |
| 1 | 2025-03-12 | -0.01 | 0.36 | 3700.00 |
| 2 | 2024-12-11 | 0.01 | 0.05 | 400.00 |
| 3 | 2024-09-11 | -0.03 | 0.11 | 466.67 |
| 4 | 2024-07-18 | -0.16 | 0.01 | 106.25 |
| 5 | 2024-03-12 | -0.06 | -0.16 | -166.67 |
| 6 | 2023-12-12 | -0.17 | -0.15 | 11.76 |
| 7 | 2023-09-13 | -0.10 | -0.19 | -90.00 |
The provided earnings data reveals significant fluctuations in both Estimated and Reported EPS over the observed quarters, with notable surprises in several instances. From September 2023 to December 2025, there is a clear trend of improvement in the company’s performance relative to expectations, despite some volatility.
Initially, in Q3 and Q4 of 2023, the company underperformed against estimates with Reported EPS worse than Estimated EPS, marked by a surprise percentage of -90.00% and 11.76% respectively. This trend of negative surprises reversed dramatically starting from March 2024, where the company began to outperform expectations significantly. For instance, in March 2024, the Reported EPS was significantly lower than estimated, at -166.67% surprise, indicating a substantial miss. However, subsequent quarters show a stark improvement, with positive surprises where Reported EPS exceeded estimates markedly—106.25% in July 2024, 466.67% in September 2024, and 400.00% in December 2024.
The most dramatic shift occurred in March 2025, with a surprise percentage of 3700.00%, indicating an exceptional outperformance compared to expectations. However, by the end of 2025, the trend reversed sharply with a -75.00% surprise in December, suggesting potential volatility or challenges in maintaining the positive momentum.
Overall, the data indicates a company experiencing significant variability in its earnings performance relative to analyst expectations, with a general trend towards improvement over the period, albeit with recent signs of potential instability.
The most recent rating changes for Outer provide a snapshot of the evolving market sentiment towards the company’s stock. On September 12, 2024, Craig Hallum upgraded Outer from “Hold” to “Buy,” setting a target price of $6. This upgrade suggests a positive shift in the firm’s outlook on Outer, possibly due to improved company fundamentals, favorable market conditions, or new growth opportunities identified by the analyst. The specified target price indicates an expectation of upward movement in Outer’s stock value, reflecting an optimistic financial forecast.
Prior to this, on November 18, 2019, The Benchmark Company initiated coverage on Outer with a status of “Speculative Buy.” However, no specific target price was provided at that time. This initiation without a target price suggests a cautiously optimistic view, acknowledging potential growth or recovery but also recognizing inherent risks and uncertainties in the company’s future performance.
These two rating changes, though spaced nearly five years apart, highlight significant moments of reassessment in investor outlook towards Outer. The long interval between these ratings also suggests periods of less analyst activity or significant shifts in company or market dynamics that necessitated reevaluation. Craig Hallum’s recent upgrade particularly underscores a likely improvement in the company’s prospects or market conditions that could encourage investment in Outer’s shares.
As of the most recent data, the current stock price stands at $7.25. This price shows a notable increase compared to the target price of $6 set by Craig Hallum following their upgrade from “Hold” to “Buy” on September 12, 2024. This suggests a positive market sentiment and potentially higher investor confidence than anticipated by Craig Hallum’s analysis.
Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.